Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

0.9292 -0.0208 (-2.19%)
Streaming Delayed Price Updated: 12:40 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seres Therapeutics Inc

< Previous 1 2 3 4 Next >
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Jefferies Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
From Seres Therapeutics, Inc. and Nestlé Health Science
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.